NCT07251426尚未招募不适用
Cold atmOspheric plaSMa Therapy Versus standArd Wound Care in Diabetic Foot and Venous Leg ulcerS - a Randomized Controlled Trial
Olaf Bakker0 个研究点目标入组 494 人开始时间: 2025年11月30日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 494
- 主要终点
- Ulcer-free survival days
研究概览
简要总结
Chronic wounds such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) pose a major health burden to the patients but also to the healthcare system because of their distorted healing capacity. This is mainly due to a prolonged treatment duration, high recurrence rates and substantial healthcare costs in wound care. Current guidelines exist that outline the standard wound care (SWC) in these patient groups but it often fails to achieve timely healing. Cold atmospheric plasma (CAP) is an emerging technology with promising antimicrobial and wound healing properties. In vitro and in vivo studies have highlighted the ability of CAP to reduce the bacterial biofilm load and stimulate tissue regeneration and microcirculation. This Randomized Controlled Trial (RCT) aims to evaluate the clinical effectiveness and cost-effectiveness of CAP in addition to SWC in patients with a DFU and VLU.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. is referred to one of the participating hospitals for treatment of a diabetic foot ulcer (DFU) or venous leg ulcer (VLU) with healing stagnation and
- •a. For VLU: i. An ulcer on the lower leg resulting from malfunctioning venous valves in the leg veins.
- •b. For DFU: i. An ulcer on the foot or lower leg in person with currently or previously diagnosed diabetes mellitus and usually accompanied by neuropathy and/or peripheral artery disease (PAD) in the lower extremity Note: In patients with both diabetes and chronic venous insufficiency, ulcers will be categorized as DFU in case of symptoms of diabetic neuropathy or loss of protective sensation, and otherwise categorized as VLU.
- •2. has a wound with a minimum wound surface area of 0.5 cm2 and a maximum diameter of 6 cm (~28 cm2 wound surface area for circular wounds; measured after debridement),
- •3. has a minimum age of 18 years old.
排除标准
- •1. the participant has one or more of the following contraindications for PLASOMA:
- •extreme exudative wounds, i.e. wounds in which moisture is visible within seconds after patting dry;
- •any implanted active electronic device, such as a pacemaker, is present;
- •an electronic medical device attached to the body, for example electronic life support equipment, a hearing aid, insulin pump or dialysis machine. If this medical device can be disconnected, PLASOMA treatment may be performed. If the sole purpose of this medical device is monitoring, such as a glucose sensor, PLASOMA treatment is not contra-indicated but note that use of PLASOMA together with such devices has not been tested and may lead to erroneous operation of the attached device during PLASOMA treatment;
- •metal in the area 10 cm around pad-electrode area, e.g. metal sutures and implants;
- •connection from outside the body to (near) the heart is present, e.g. a central venous catheter;
- •the participant has epilepsy;
- •the participant is pregnant.
- •2. the participant has more than one wound that requires professional wound care.
- •3. for DFU the WIfI-classification is wound grade 3, defined as an extensive, deep ulcer involving forefoot and/or midfoot; deep, full thickness heel ulcer + calcaneal involvement.
- •4. presence of ischemia grade 2 or 3, according to the WIfI classification (= the ankle-brachial pressure index (ABI) is ≤0.59 OR the ankle systolic pressure is ≤69 mmHg OR the toe pressure is ≤39 mmHg; there should be at least one of these three measurements available).
- •5. a deep infection defined as an infection of the wound involving structures deeper than skin and subcutaneous tissues (e.g., abscess, osteomyelitis, septic arthritis, fasciitis).
- •6. the wound is located on a toe.
- •7. the participant receives treatment with immunosuppressive agents or oral corticosteroids; no exclusion if participant has received a stable dose for at least 2 months and the oral corticosteroid dose does not exceed 7.5 mg/day prednisone or equivalent.
- •8. the participant is receiving or likely to receive offloading with a total contact cast or advanced wound therapies - such as negative pressure therapy, hyperbaric oxygen therapy, biologicals (e.g. skin substitutes, growth factors), electrophysical therapy - for the to be-treated wound. Advanced wound dressings (including but not limited to hydrocolloid, hydrogel, alginate, collagen and antimicrobial dressings) are not excluded.
- •9. presence of a chronic or active skin disorder that may negatively influence wound healing (such as Marfan or Ehlers-Danlos syndrome).
- •10. the participant takes part in another study that is likely to compromise the outcome of this study or the feasibility of the participant fulfilling this study.
- •11. the participant is lactating.
- •12. the participant is unable to provide consent.
研究组 & 干预措施
Cold atmospheric Plasma
Experimental
Cold Atmospheric Plasma Treatment 2x per week
干预措施: COLD ATMOSPHERIC PLASMA (Device)
Standard Wound Care
No Intervention
The use of standardized wound care 2x per week
结局指标
主要结局
Ulcer-free survival days
时间窗: 26 weeks
number of days within the follow-up period (until 26 weeks after the start of the treatment) where the participant is alive and has no ulcer on the same anatomical location of the same foot or limb
次要结局
- Quality of Life (QoL)(baseline, 13 weeks and 26 weeks)
- Wound Quality of Life (Wound-QoL)(baseline, 13 weeks, 26 weeks)
- Wound healing rate(26 weeks)
- time to wound healing(26 weeks)
- Surface area reduction(26 weeks)
- Recurrences(26 weeks)
- Development of new ulcers(26 weeks)
- Wound pain(26 weeks)
- Wound infection(26 weeks)
- Occurence of adverse events(26 weeks)
- presence of amputations(26 weeks)
- Cost of Care(26 weeks)
- Cost Effectiveness(26 weeks)
研究者
Olaf Bakker
Principal Investigator
St. Antonius Hospital
相似试验
Unknown
不适用
Cold Plasma Therapy for Acceleration of Wound Healing in Diabetic FootDiabetic FootNCT04205942Ruhr University of Bochum65
撤回
不适用
Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer PatientsVenous Leg UlcerNCT02912858Firstkind Ltd
已完成
1 期
Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein CirculationVenous DiseaseVenous Vascular Diseases and SyndromesVenous InsufficiencyVenous UlcersNCT01509599Medical University of South Carolina197
已完成
不适用
Comparison of Vacuum Assisted Closure and Saline Dressing in Patients With Diabetic Foot UlcersDiabetic FootNCT06450015Children Hospital and Institute of Child Health, Lahore88
已完成
不适用
Larval Debridement Therapy Versus Sharp Debridement to Remove BiofilmLower Extremity or Diabetic Foot UlcersBacterial InfectionNCT02294175North Florida Foundation for Research and Education45